Dr Andrew Rut at MyMeds&Me outlines to ICT Magazine the ways in which pharmaceutical companies must approach patient data safety in clinical trials

Dr Andrew Rut at MyMeds&Me outlines to ICT Magazine the ways in which pharmaceutical companies must approach patient data safety in clinical trials

News
31/08/18

ICT: Would you say that attitudes towards data protection are hardening? If so, why? 

Dr Andrew Rut: Data privacy is one of the most contentious issues of our time. Global attitudes towards the protection and ownership of personal data are toughening, and this is reflected in increased regulation. For example, the EU’s General Data Protection Regulation (GDPR), which was introduced in May 2018, expands existing rules in areas such as patient consent and imposes tough penalties for noncompliance. 

The shift is happening because, while new technologies have enabled the capture of data at an unprecedented volume and rate, adequate systems to protect individuals’ personal information have not always developed in step. High-profile data breaches − such as SingHealth, where 1.5 million healthcare patients, including the Singaporean prime minister, had their personal data leaked − have raised awareness of the huge value of data and the need for increasingly robust security measures to protect it.

This article is taken from International Clinical Trials September 2018, pages 18-19. © Samedan Ltd.

Read the full article here: http://www.samedanltd.com/maga... 


Access Free Demo

Plus get a fixed price pilot — fill in the details below:

For more information contact andywatson@mymedsandme.com

Keep informed

For expert insight and updates from the MyMeds&Me team.

We respect your privacy and we will only use your email address for newsletters and company updates